Metoclopramide Mercury Pharmaceuticals (Ireland)

Metoclopramide, the active ingredient in Metoclopramide Mercury Pharmaceuticals, is a dopamine antagonist presented as an injectable solution for intramuscular or intravenous use. It treats nausea, vomiting and gastric motility disorders in adult patients.

GNH USA supplies Metoclopramide Mercury Pharmaceuticals as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopamine pathways that trigger nausea and delay gastric emptying. It is employed in several well‑established clinical situations.

- Nausea and vomiting: reduces frequency and severity of episodes. - Post‑operative nausea and vomiting: prevents symptoms after surgical procedures. - Gastroparesis: enhances gastric emptying and improves digestive symptoms. - Migraine‑associated nausea: alleviates nausea accompanying migraine attacks.

Metoclopramide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Restlessness or agitation - Diarrhea - Headache - Dizziness

Serious or Rare Side Effects: - Acute dystonia or other extrapyramidal symptoms - Neuroleptic malignant syndrome - Severe depression or suicidal thoughts - Tardive dyskinesia with long‑term use - Anaphylactic reaction - Marked hypotension

Before initiating therapy, clinicians should consider several safety factors.

- Assess renal and hepatic function: adjust use in impairment. - Review history of movement disorders: avoid in patients prone to extrapyramidal reactions. - Monitor for depression or suicidal ideation: discontinue if severe. - Use caution with other dopamine‑blocking agents: increased risk of motor side effects. - Avoid in patients with known hypersensitivity to metoclopramide: discontinue immediately. - Store at ambient temperature: keep in original container, protect from light and moisture.

Metoclopramide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): additive extrapyramidal effects. - CYP2D6 substrates (e.g., codeine): increased plasma concentrations.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Alcohol: may increase drowsiness and dizziness.